A published monthly medication price is useful, but it is not the same thing as a complete treatment agreement. Tri Valley Plastic Surgery makes that distinction especially relevant: its semaglutide and tirzepatide pages disclose introductory and subsequent monthly prices, while also offering four- and seven-month packages without publishing their financial terms. For someone considering enrollment, the central question is not simply what the first month costs. It is what authorizes the next charge, what services that charge buys and what happens if treatment does not continue.
This review examines the practice’s public documentation consulted October 19, 2026. Tri Valley Plastic Surgery is a plastic surgery and Med Spa business in Dublin, California, with an expressly advertised GLP-1 offering—not merely a cosmetic practice mentioning weight loss. Its documentation describes evaluation, monthly monitoring and medication access. However, it does not identify the specific products or dispensing pharmacies, or provide a complete GLP-1 cancellation and refund agreement. Those gaps warrant written clarification rather than assumptions about either favorable or unfavorable terms.
At a glance
- Semaglutide pricing
- The initial consultation is $50. Medication is advertised at $500 for the first month and $600 for each subsequent month; the complete list of included services is not specified.Sources: [6]
- Tirzepatide pricing
- Tirzepatide is advertised at $700 for the first month and $800 for each subsequent month. The documentation does not establish whether the $50 consultation fee applies identically.
- Packages and financing
- Both programs advertise four- and seven-month packages and financing, but public passages do not disclose package prices, payment schedules or minimum commitments.
- Care access
- The practice advertises virtual and in-person consultations, monthly follow-up and extended-hours medication pickup; out-of-state clinical availability is not established.
- Surgery-credit conditions
- A semaglutide promotion offers 50% of program expenses as a future surgery credit after reaching target weight, with a minimum $5,000 surgeon fee and a maximum $3,600 credit.Sources: [4]
Start with the treatment agreement, not the website terms
Tri Valley Plastic Surgery’s website terms say they were last updated January 1, 2026, and describe the site’s materials as general information rather than comprehensive documentation. That limitation matters here. The terms principally govern website use; a provision about terminating website access does not establish how a patient cancels medication treatment. The consulted documentation does not supply program-specific rules for automatic renewal, pauses, refunds or unused medication. It therefore cannot support a conclusion that enrollment is either automatically renewing or freely cancelable.
Before paying, request the actual agreement governing the selected program and package. It should identify when enrollment becomes binding, what payment is authorized and whether later charges require a new decision. A consultation booking, a prescription and a package purchase may involve different responsibilities, but these pages do not explain where those boundaries fall. Our guide to terms to review before enrollment provides a useful framework for organizing those questions without treating missing language as a hidden contractual obligation.
The distinction is practical rather than merely technical. Someone who decides not to continue needs to know whether notice stops future appointments, future medication orders, future charges or all three. No minimum cancellation-notice deadline is documented in the consulted passages. Nor is there a published promise that stopping treatment produces a refund. Ask for the cancellation channel and effective date in writing, along with the treatment of money already collected.
The advertised prices establish a starting point, not an all-in bill
The semaglutide page separates a $50 initial consultation from medication priced at $500 for the first month and $600 for each subsequent month. Tirzepatide is advertised at $700 for the first month and $800 for each subsequent month. These are explicit introductory and later prices, not “starting at” figures in the quoted passages. They are described by month, not by four-week billing periods. The pages do not explain exact collection dates or whether calendar-month anniversaries determine later billing.
The booking page also describes a $50 weight-loss-provider consultation, but the documentation does not conclusively establish how that charge applies to tirzepatide enrollment. Likewise, the monthly medication prices do not settle whether follow-up appointments, laboratory work, injection supplies or other services are included. Readers should not assume either that every item is bundled or that every item costs extra. A written, itemized quote should resolve the difference before the first payment is authorized.
Insurance is another separate question. The consulted GLP-1 pages do not specify insurance billing, medication coverage or assistance arrangements. Information elsewhere about insurance for unrelated procedures would not establish coverage for these programs. Ask which amounts are collected directly, whether any claims are submitted and what documentation is available for the patient’s plan. The published prices remain useful, but they are not proof of an insured benefit or a complete out-of-pocket estimate.
| Item | Publicly stated price or structure | Clarification to request |
|---|---|---|
| Initial consultation | $50 on the semaglutide and booking pages | Application to tirzepatide and treatment of the fee if no prescription follows |
| Semaglutide medication | $500 first month; $600 each subsequent month | Exact product, quantity, included services and collection dates |
| Tirzepatide | $700 first month; $800 each subsequent month | Exact product, quantity and any separate consultation or monitoring charges |
| Treatment packages | Four- and seven-month options for both programs | Total price, payment schedule, commitment and early-exit terms |
| Financing | Available; details provided on request or at consultation | Financing agreement, interest, fees and effect of treatment changes |
Four- and seven-month packages need their own explanation
Both medication pages advertise four- and seven-month treatment packages. Neither quoted passage publishes package prices or establishes a discount. More importantly, package duration alone does not establish how much medication is supplied, whether the entire amount is collected upfront or whether the patient has a minimum treatment commitment. Those are separate terms. The monthly prices should not be multiplied into an assumed package quote, and a package should not be described as mandatory prepayment without supporting language.
Semaglutide financing details, including a payment calculator, are available upon request. The tirzepatide page says financing information can be provided during the consultation. That documents an option, not its cost or suitability. Ask for the financing provider, payment schedule, interest and fees, and what happens to the balance if prescribing changes or treatment ends. A treatment decision and a financing obligation should be understood separately; the public descriptions do not explain how they interact.
For comparison purposes, request a written description of ordinary monthly enrollment alongside each package. It should say whether either route renews automatically, which benefits differ and whether medication or appointments can be paused. Our explanation of monthly prices versus ongoing commitments is particularly relevant here. The practice publishes enough to identify multiple purchasing structures, but not enough to conclude which offers more flexibility or a lower overall cost.
Identify the medication and the party supplying it
Tri Valley Plastic Surgery expressly offers semaglutide and tirzepatide, but the consulted pages do not identify a brand, manufacturer, presentation or dispensing pharmacy. They also do not establish whether the products are compounded. A reference to “Ozempic face” elsewhere is not evidence that Ozempic is dispensed. Before agreeing to recurring medication charges, ask for the exact prescribed product, formulation, route, quantity and pharmacy, as well as the party responsible for replacements or questions about the medication received.
The access descriptions need reconciliation. The getting-started page says patients receive shots at monthly appointments and also advertises extended-hours medication pickup. The semaglutide page says a patient may leave the consultation with medication if the evaluation is favorable. These statements document possible access routes, not a dosing schedule. They do not explain who administers each injection, what supplies or instruction accompany take-home medication, or whether the monthly appointment and medication-dispensing schedules are the same.
FDA approval applies to a specific product, not to a practice or to an ingredient name in the abstract. Compounded preparations are not FDA approved, although nonapproval alone does not establish clinical inequivalence. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. That context makes product identification important; it does not establish that this practice uses compounded medication. The product-description guide explains the distinctions to clarify.
What the practice promises about evaluation and follow-up
The semaglutide pathway begins with a PA reviewing weight-loss goals and medical history. The practice describes a comprehensive health assessment and a program tailored to individual health needs and goals. It says Steven Williams oversees the semaglutide program. These are meaningful descriptions of a clinician-led process, but they do not identify who writes every prescription or personally conducts each follow-up. A patient should ask who will be responsible for routine decisions, treatment concerns and coverage when the usual clinician is unavailable.
Monthly follow-up is described for both programs. Semaglutide visits track progress, while tirzepatide check-ins are described as reviewing weight, blood sugar and other relevant health indicators after the initial prescription. The tirzepatide assessment considers health history, goals and lifestyle. Its page also encourages physical activity and balanced eating, but that does not establish an included dietitian or structured nutrition service. The agreement should distinguish promised monitoring from optional services and identify any charges beyond the medication price.
Both pages discuss treatment for people without diabetes, but they do not publish complete eligibility criteria, age requirements or required testing. Those statements should not be treated as personal eligibility clearance. NIDDK explains that medication selection involves health conditions, other medicines, benefits, side effects and costs. For enrollment purposes, ask what happens financially if the evaluation does not support prescribing, or if later monitoring leads the treating clinician to change the plan. The public pages do not answer those questions.
Promotional credits are conditional, not cash refunds
The practice connects semaglutide enrollment with a future surgery promotion: after reaching target weight, 50% of program expenses can be credited toward upcoming surgery. The surgery must have a minimum surgeon fee of $5,000, and the maximum credit is $3,600. This is a conditional credit toward another service, not a reduction in the published medication charges or a cash-back promise. The consulted passage does not explain expiration, which program expenses qualify or how target-weight attainment is documented.
A separate referral promotion offers $200 in credit when a referred patient enrolls in the semaglutide program. It can be used toward treatments or services except skincare and neurotoxin banks. The practice says the promotion can be combined with others and that multiple successful referrals generate additional credits. By contrast, the Med Spa’s $100 new-patient promotion expressly excludes weight-loss treatments and neurotoxin banks. It should not be deducted from the advertised GLP-1 prices.
Skin tightening and body contouring are also advertised as post-weight-loss support, but the pages do not say those treatments are included with medication. Related services receive customized quotes after a physical assessment and medical review. Their published candidate characteristics belong to post-weight-loss procedures, not automatically to GLP-1 enrollment. Before relying on any credit, obtain the current promotion conditions in writing, including service eligibility and expiration. No expiration date is established for the cited semaglutide promotions.
Local access is documented; nationwide delivery is not
The practice describes serving the Bay Area and international patients from Dublin, California. Its main office is listed at 11820 Dublin Boulevard, with weekday hours of 8 a.m. to 5 p.m. The Med Spa is listed separately at 11828 Dublin Boulevard: Monday through Wednesday, 8 a.m. to 5 p.m.; Thursday until 7 p.m.; Friday until 6 p.m.; and Saturday, 9 a.m. to 5 p.m. Ask which location handles GLP-1 appointments and pickup rather than assuming every posted hour applies.
Virtual and in-person consultations are advertised, and the booking page asks patients who prefer virtual care to mention that preference in the notes. This does not establish clinical availability outside California, and the consulted pages do not list authorized states. Nor do they document home shipping, shipping charges or dispatch and arrival times. Local pickup is the confirmed option. If remote enrollment is important, establish both whether the practice can treat someone in the relevant state and how medication would actually be obtained.
For appointments that do not fit the online options, the booking page lists (925) 875-9011. Website-accessibility accommodation questions have a separate number, (925) 875-0700. Neither listing establishes an urgent clinical support service or a response-time promise. Ask for the appropriate channel for symptoms, billing disputes and medication problems. If an injectable GLP-1 product is ever shipped and arrives warm or inadequately refrigerated, FDA explicitly advises not using it and contacting the provider or dispensing pharmacy.
What would make enrollment sufficiently clear
The practice presents Steven Williams as a board-certified plastic and reconstructive surgeon and diplomate of the American Board of Plastic Surgery. It presents Philip Wasicek as a double board-certified plastic surgeon focused on facial aesthetic surgery. These are provider-stated credentials, not independently verified findings in this review. Williams’s stated oversight of semaglutide is directly relevant; the broader surgical roster does not establish who will prescribe, answer questions or manage each patient’s weight-loss treatment.
A useful enrollment document would combine the selected product and pharmacy with an itemized price, appointment schedule, medication-access process and clear exit terms. It would also explain any financing obligation and promotional credit separately. That would allow a prospective patient to evaluate the actual offer rather than assembling a contract from marketing pages. Contract clarity would still not prove clinical outcomes: the consulted documentation does not establish measured results for this program, and cosmetic-procedure testimonials should not substitute for that evidence.
Questions & answers
Is the $50 consultation credited toward semaglutide?
The page states a $50 initial consultation fee separately from medication priced at $500 for the first month. It does not say that the consultation fee is credited toward medication, refunded if no prescription follows or included in a package. Ask for those terms before booking. The tirzepatide page does not independently establish identical consultation-fee treatment.
Does a four-month package require four months of payments?
The public description does not establish that. Four- and seven-month packages are advertised for both medications, but package duration alone does not prove a minimum financial commitment, upfront collection or a particular medication quantity. Request the package price, payment schedule and early-exit rules rather than treating the package label as the complete agreement.
Can I cancel and receive a refund for unused medication?
The consulted documentation does not provide a GLP-1-specific cancellation or unused-medication refund policy. Website-access termination language is not a treatment cancellation policy. Ask how cancellation must be submitted, when it becomes effective and whether already collected payments or prepared medication are refundable. Do not assume that permission to stop future treatment also guarantees repayment.
Will I receive medication at the first consultation?
The semaglutide page says patients may leave with medication if the evaluation is favorable; it does not guarantee immediate dispensing. The booking page also describes monthly injection appointments and extended-hours pickup. Confirm availability, the exact product, the pickup location and any instruction or supplies provided before planning around same-day medication access.
Can the surgery credit pay for the entire surgeon fee?
The published conditions do not support that interpretation. The credit is 50% of semaglutide program expenses, capped at $3,600, and the qualifying surgery must have a surgeon fee of at least $5,000. It is tied to reaching target weight. Ask which expenses qualify and what other surgical charges remain; it is not a cash refund.
Can I enroll virtually from another state?
Virtual consultations are advertised, and the booking instructions ask patients to note that preference. However, the consulted documentation does not list states where GLP-1 care is available or establish home delivery. Confirm clinical availability for your location and the medication-access arrangement directly. The practice’s broader statement about serving international patients does not settle those program-specific questions.
Our assessment
Tri Valley Plastic Surgery provides several useful enrollment basics: named medications, distinct introductory and subsequent prices, a described clinical evaluation, monthly monitoring and local pickup options. Its conditional promotions are also more specific than a simple savings headline. The principal weakness is contractual completeness. Product identity, pharmacy responsibility, package economics, included services and cancellation or refund boundaries remain unresolved in the consulted documentation. That is not evidence of unfavorable terms, but it prevents a confident assessment of the full commitment. A prospective patient’s most useful next step is to obtain one written offer that connects the selected treatment to its payment schedule, service responsibilities and exit rules before authorizing charges.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Tri Valley Plastic Surgery — get started with weight loss ↗
- Tri Valley Plastic Surgery — weight loss shots/post weight loss ↗
- Tri Valley Plastic Surgery — about/about tri valley plastic surgery ↗
- Tri Valley Plastic Surgery — weight loss shots/semaglutide ↗
- Tri Valley Plastic Surgery — weight loss shots/tirzepatide ↗
- Tri Valley Plastic Surgery — weight loss shots/ozempic face ↗
- Tri Valley Plastic Surgery — official website ↗
- Tri Valley Plastic Surgery — terms and conditions ↗